Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury

  1. Escribá, P.V.
  2. Gil-Agudo, Á.M.
  3. Vidal Samsó, J.
  4. Sánchez-Raya, J.
  5. Salvador-de la Barrera, S.
  6. Soto-León, V.
  7. León-Álvarez, N.
  8. Méndez Ferrer, B.
  9. Membrilla-Mesa, M.D.
  10. Redondo Galán, C.
  11. Benito-Penalva, J.
  12. Montoto-Marqués, A.
  13. Medel Rebollo, J.
  14. Palazón García, R.
  15. Gutiérrez Henares, F.
  16. Miralles, M.
  17. Torres, M.
  18. Nieto-Librero, A.B.
  19. García Marco, D.
  20. Gómez, C.
  21. Jimeno, D.
  22. Oliviero, A.
Zeitschrift:
Spinal Cord

ISSN: 1476-5624,  1362-4393

Datum der Publikation: 2024

Ausgabe: 62

Nummer: 8

Seiten: 454-467

Art: Artikel

DOI: 10.1038/S41393-024-01006-4 GOOGLE SCHOLAR lock_openOpen Access editor